Back to Results
First PageMeta Content
Clinical research / Design of experiments / Epidemiology / Nursing research / Medical technology / Health technology assessment / Clinical trial / National Institute for Health Research / Randomized controlled trial / Medicine / Health / Research


HTA noL-ornithine-l-aspartate (LOLA) and/or Rifaximin for acute hepatic encephalopathy in patients with cirrhosis Introduction The aim of the HTA Programme is to ensure that high quality research information on
Add to Reading List

Document Date: 2015-03-06 03:13:40

Open Document

File Size: 137,61 KB

Share Result on Facebook

Company

HTA / /

Country

United Kingdom / Northern Ireland / Scotland / Wales / /

/

Facility

National Institute / /

IndustryTerm

health technology / outline applications / on-line application form / enzyme systems / patient management / suitable methodological support services / Health technology assessment / diagnostic and imaging techniques / research grant applications / medicinal products / health technology assessment projects / /

MedicalCondition

acute hepatic encephalopathy / overt encephalopathy / liver failure / severe cirrhosis / chronic encephalopathy / cirrhosis / hepatic encephalopathy / cirrhosis suffering / metabolic dysfunction / Liver disease / /

Organization

National Institute for Health Research / HTA Commissioning Board / MHRA / Commissioning Board / Public Health Agency in Northern Ireland / NIHR Research Design Service / NHS / Medical Research Council / /

Position

Governor / qualified Trial Manager for appropriate projects / chief investigator / qualified Trial Manager / /

Product

Programme / lactulose / /

Region

Northern Ireland / /

Technology

health technology / /

URL

www.nets.nihr.ac.uk/ppi / http /

SocialTag